High dose, short course prednisolone for acute idiopathic thrombocytopenic purpura (ITP) in children

Aparna Jayaraman; Sarthak Das; Niranjan Biswal; Dillikumar C. G.; Bhavna Ashok Bade

doi:10.18203/2349-3291.ijcp20173770

Authors

Aparna Jayaraman Department of Pediatrics, ESIC Medical College and PGIMSR, Chennai, Tamil Nadu, India
Sarthak Das Department of Pediatrics, JIPMER, Karaikal, Puducherry, India
Niranjan Biswal Department of Pediatrics, JIPMER, Karaikal, Puducherry, India
Dillikumar C. G. Department of Pediatrics, JIPMER, Karaikal, Puducherry, India
Bhavna Ashok Bade Department of Pathology, JIPMER, Karaikal, Puducherry, India

DOI:

https://doi.org/10.18203/2349-3291.ijcp20173770

Keywords:

Acute, Adverse effects, High dose prednisolone, ITP

Abstract

Background: Immune thrombocytopenia (ITP) is a relatively benign and self-limiting condition. Though its dramatic presentation with skin or mucosal bleeds could be worrisome, the incidence of serious bleeding like intracranial hemorrhage (ICH) is relatively low (<1%) occurs at a very low count of <20,000 /mm³. The aim of the study was to compare a high dose, short course prednisolone with conventional Prednisolone therapy in the treatment of acute ITP of childhood.

Methods: 20 cases and 18 retrospective controls with acute ITP were enrolled. The study group received 5mg/kg/day of oral prednisolone for four days. All the controls had received 2mg/kg/day of oral prednisolone for 14 days, tapered and stopped over the third week.

Results: The study group was found to have significant decrease in clinical bleeding, (p=0.02), and significant increase in platelet count by day 3 of treatment (p=0.03) but no significant difference in platelet counts on day 7 of treatment (p=0.07) when compared with the control group.

Conclusions: We conclude that the high dose short course oral prednisolone is significantly better than the conventional regimen in reducing clinically significant bleeding and raising the platelet count to safe levels within first 72 hours of therapy.

Metrics

Metrics Loading ...

References

Wilson DB. Acquired platelet disorders. Nathan and Oski-Textbook of hematology of infancy and childhood. 6th ed.1600-10.

Cines DB, Blanchette VS. Medical progress: Immune Thrombocytopenic Purpura. New Eng J Med. 2002;346:995-1008.

Buchanan GR, Holtkamp CA. Prednisone therapy for children with newly diagnosed idiopathic thrombocytopenic purpura: a randomized clinical trial. Am J Pediatr Hematol Oncol. 1984;6:355-61.

Lilleyman JS. Platelet Disorders. Pediatric Hematology. 2nd ed:442-47.

Carcao MD, Zipursky A, Butchart S, Leaker M, Blanchette VS. Short-course oral prednisone therapy in children presenting with acute immune thrombocytopenic purpura (immune thrombocytopenic purpura). Acta Paediatr Suppl 1998;424:71-4.

Blanchette V, Adams M, Wang E, McMillan J, Imbach P, Andrew M, et al. Randomised trial of intravenous immunoglobulin G, intravenous anti-D, and oral prednisone in childhood acute immune thrombocytopenic purpura. Lancet. 1994;344(8924):703-7.

Cheng Y, Wong RS, Soo YO, Chui CH, Lau FY, Chan NP,et al. Initial treatment of immune thrombocytopenic purpura with high-dose dexamethasone. New Eng J Med. 2003;349(9):831-6.

Wei Y, Ji XB, Wang YW, Wang JX, Yang EQ, Wang ZC, et al. High-dose dexamethasone vs prednisone for treatment of adult immune thrombocytopenia: a prospective multicenter randomized trial. Blood. 2016;127(3):296-302.

Neunert C, Lim W, Crowther M, Cohen A, Solberg L, Crowther MA. The American Society of Hematology 2011 evidence-based practice guideline for immune thrombocytopenia. Blood. 2011;117:4190-207.

Ozsoylu S, Sayli TR, Oztürk G. Oral megadose methylprednisolone versus intravenous immunoglobulin for acute childhood idiopathic thrombocytopenic purpura. Pediatr Hematol Oncol. 1993;10(4):317-21.

Suarez CR, Rademaker D, Hasson A, Mangogna L. High-dose steroids in childhood acute idiopathic thrombocytopenia purpura. Am J Pediatr Hematol Oncol. 1986 Summer;8(2):111-5.

Provan D, Stasi R, Newland AC, Blanchette VS, Bolton-Maggs P, Bussel JB, et al. International consensus report on the investigation and management of primary immune thrombocytopenia. Blood. 2010;115:168-86.